SCHEMBL5525354

SCHEMBL5525354

CC(C)(C)OC(=O)Nc1cccc(C(=O)N(CCC2CCCCC2)C(=O)NCC#N)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 2/20 0.45
ALDH1A1 P00352 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CTSS P25774 5/20 0.42
CTSK P43235 5/20 0.42
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
NPC1 O15118 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5517734 0.89 CTSK (0.45) ALDH1A1KMT2ASMN1; SMN2CTSSCTSK
SCHEMBL6874225 0.88 CASR (0.48) CASRALDH1A1KMT2AMEN1CYP1A2
SCHEMBL5525348 0.87 CASR (0.43) CASRALDH1A1KMT2AMEN1CYP1A2
SCHEMBL5521755 0.84 PRMT5 (0.42) CASRCTSSCTSKPRMT5WDR77
SCHEMBL5530670 0.84 HPGD (0.42) ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL5522991 0.81 CTSK (0.43) CASRALDH1A1KMT2AMEN1CYP1A2
SCHEMBL6875724 0.81 CTSK (0.52) CASRCTSSCTSKHDAC1HDAC6
SCHEMBL5533909 0.75 CTSK (0.50) ALDH1A1KMT2AMEN1MAPTCTSS
SCHEMBL5517729 0.75 CTSS (0.37) ALDH1A1KMT2AMEN1SMN1; SMN2CTSS
SCHEMBL5525358 0.74 PRMT5 (0.51) SMN1; SMN2CTSSCTSKPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CASR 2183/4885ALDH1A1 4049/4885KMT2A 2983/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 CASR 2183/4885ALDH1A1 4049/4885KMT2A 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.